ArticleJACC. Asia2023
Asia-Pacific Investigators and Asian Enrollment in Cardiometabolic Trials: Insights From Publications Between 2011 and 2020.
Article in JACC. Asia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Drivers of Atherosclerotic Cardiovascular Disease in South Asians: Current Insights and Future Directions.JACC. Asia · 2026Review
- Race and Ethnicity in Cardiovascular Disease Risk Prediction for Multiethnic Populations: Insights From Global Guidelines.JACC. Asia · 2026Review
- Joint analysis of hemoglobin-to-RDW and creatinine-to-albumin ratios for mortality prediction in critical heart failure.iScience · 2026Article
- Heart Failure Quality of Care Among Asian Patients in the United States.Journal of the American College of Cardiology · 2026Article
- Heart Failure in Asian Populations.JACC. Asia · 2025Article
- The Asia Pacific Cardiovascular Research (ASPIRE) Network: Facilitating and Advancing Regional Cardiovascular Clinical Trials.JACC. Asia · 2025Article
- Predictive Modeling of Heart Failure Outcomes Using ECG Monitoring Indicators and Machine Learning.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025Article
- Two-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF Program.Clinical cardiology · 2025Article
- Current and Future of Heart Failure Care in Asia.International journal of heart failure · 2024Review
- Reply: Low Asian Enrollment in Cardiometabolic Studies and the Importance of Trial Context.JACC. Asia · 2024Article
- Low Asian Enrollment in Cardiometabolic Studies and the Importance of Trial Context.JACC. Asia · 2024Article
- Adverse Events and Clinical Correlates in Asian Patients with Atrial Fibrillation and Diabetes Mellitus: A Report from Asia Pacific Heart Rhythm Society Atrial Fibrillation Registry.Journal of clinical medicine · 2024Article
- The Inclusion of Underrepresented Populations in Cardiovascular Genetics and Epidemiology.Journal of cardiovascular development and disease · 2024Review
- Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Role of Regional/Ethnic Differences: Focus on Asia.JACC. Asia · 2024Article
- Promoting Healthy Longevity Should Start Young: A Life Course Journey.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2024Article
- Disparities in Representation of Asian Participants and Investigators in Cardiometabolic Trials.JACC. Asia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A lack of geographic and racial diversity in clinical trial populations may arise from a disproportionate focus on the United States and Europe for trial leadership and conduct. Inadequate diversity may compromise the external validity to the Asia-Pacific (APAC) region, where 60% of global cardiometabolic disease exists. Objectives: This study aimed to assess the proportion and trends of Asian race participants and APAC authorship in cardiometabolic trials. Methods: We performed a systematic review of all cardiovascular, diabetes and obesity-related randomized controlled trials (phase ≥2, n = ≥100) published in these major medical journals: the Results: A total of 8.3% (218,613 of 2,619,710) participants identified as being of Asian race and 7.7% of total enrollment occurred in APAC. APAC lead authorship occurred in 52 of 656 (7.9%) trials and collaboration in 10.1% (1312 of 13,000 of authors), which correlated with Asian enrollment ( Conclusions: Despite a favorable trend over the past decade, Asian participants and authors from APAC remain significantly underrepresented in seminal cardiometabolic trials; barriers to trial conduct and leadership in this region must be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.